Published in Oncol Lett on July 27, 2016
Tissue-Specific MicroRNA Expression Patterns in Four Types of Kidney Disease. J Am Soc Nephrol (2017) 0.75
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
Most mammalian mRNAs are conserved targets of microRNAs. Genome Res (2008) 37.16
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol (2007) 9.65
The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer (2012) 4.72
Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci U S A (2010) 2.47
MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis (2012) 2.32
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res (2005) 2.31
Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One (2012) 2.06
MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br J Cancer (2012) 1.90
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther (2008) 1.88
MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem (2011) 1.88
Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res (2011) 1.86
Insulin and its receptor: structure, function and evolution. Bioessays (2004) 1.64
Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene (2013) 1.55
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A (2013) 1.53
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res (2010) 1.43
Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res (2008) 1.40
Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16(INK4A). Int J Cancer (2010) 1.34
Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci U S A (2013) 1.32
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett (2010) 1.27
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett (2012) 1.24
Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther (2010) 1.20
Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res (2012) 1.20
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Mol Cancer Ther (2011) 1.19
miR-486 sustains NF-κB activity by disrupting multiple NF-κB-negative feedback loops. Cell Res (2012) 1.17
Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res (2011) 1.16
Hepatitis C virus Core protein overcomes stress-induced premature senescence by down-regulating p16 expression via DNA methylation. Cancer Lett (2012) 0.97
Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer. Mol Cancer (2014) 0.94
MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1. FEBS J (2014) 0.94
miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. FEBS Lett (2012) 0.88
Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type I insulin-like growth factor receptor in vitro and in an orthotopic model. Hepatol Res (2007) 0.85
Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res (2011) 0.84
Repression of miR-17-5p with elevated expression of E2F-1 and c-MYC in non-metastatic hepatocellular carcinoma and enhancement of cell growth upon reversing this expression pattern. Biochem Biophys Res Commun (2013) 0.83
Aberrant DNA methylation in hepatocellular carcinoma tumor suppression (Review). Oncol Lett (2014) 0.83
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. Anticancer Drugs (2013) 0.82
IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis (review). Oncol Rep (2014) 0.78